Complex polyamines: unique prion disaggregating compounds.
Among the candidate anti-prion chemotherapeutic agents identified to date, complex polyamines constitute the only class of compounds that possess the ability to remove pre-existing PrP(Sc) molecules from infected cells. The potency of branched polyamines such as cationic dendrimers increases with the density of positive charges on their surface. Cationic dendrimers appear to accumulate together with PrP(Sc) molecules in lysosomes, where the acidic environment facilitates dendrimer-mediated PrP(Sc) disaggregation. Dendrimers can disaggregate a range of different amyloid proteins by interacting with specific epitopes on each protein. Studies with model peptides suggest that dendrimers may cause fiber breakage and capping of elongating fibers. Potential limitations to the development of dendrimers as therapeutic compounds for neurodegenerative disorders of protein misfolding such as prion diseases include poor bioavailability, limited spectrum of activity, and detrimental neurological side effects. A related group of compounds, lipopolyamines, are smaller molecules containing a lipophilic tail that may assist membrane targeting. Developing strategies to enable the safe delivery of potent complex polyamines to the central nervous system represents a critical avenue for future research.
Supattapone
Surachai
S
Department of Biochemistry, Dartmouth Medical School, Hanover, New Hampshire 03755, USA. supattapone@dartmouth.edu
Piro
Justin R
JR
Rees
Judy R
JR
D000818:Animals; D002417:Cattle; D050091:Dendrimers / Q000627:therapeutic use*; D006041:Goats; D006801:Humans; D011073:Polyamines / Q000627:therapeutic use*; D018621:PrPC Proteins / Q000378:metabolism; D018620:PrPSc Proteins / Q000378:metabolism; D017096:Prion Diseases / Q000188:drug therapy*; D011328:Prions / Q000378:metabolism; D012756:Sheep
D050091:Dendrimers; D011073:Polyamines; D018621:PrPC Proteins; D018620:PrPSc Proteins; D011328:Prions
Biochemistry. 1989 Oct 17;28(21):8380-8
2574992
Science. 2003 Oct 31;302(5646):871-4
14593181
J Cell Sci. 2008 Mar 15;121(Pt 6):773-83
18285446
Biol Chem. 2000 May-Jun;381(5-6):463-9
10937879
Macromol Biosci. 2007 Aug 7;7(8):1047-59
17595681
J Virol. 2001 Apr;75(7):3453-61
11238871
Mol Pharm. 2006 Sep-Oct;3(5):614-27
17009860
FEBS Lett. 2004 Nov 5;577(1-2):127-33
15527773
J Biol Chem. 2007 Dec 14;282(50):36341-53
17940287
Mol Biotechnol. 1999 Nov;13(1):45-55
10934521
J Biomater Sci Polym Ed. 2006;17(1-2):3-19
16411595
Biochem Biophys Res Commun. 2006 Jun 23;345(1):21-8
16674918
Science. 2000 Feb 25;287(5457):1503-6
10688802
Nature. 1967 Sep 2;215(5105):1043-4
4964084
Cell. 2005 Apr 22;121(2):195-206
15851027
Expert Rev Anti Infect Ther. 2007 Aug;5(4):613-30
17678425
Eur J Biochem. 1988 Sep 1;176(1):21-30
3138115
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13363-83
9811807
J Med Chem. 2005 Mar 10;48(5):1414-20
15743185
Science. 1994 Apr 22;264(5158):530-1
7909169
Proc Natl Acad Sci U S A. 1986 Sep;83(17):6372-6
3462700
Vet J. 2000 Jan;159(1):10-7
10640408
Cell. 1987 Oct 23;51(2):229-40
2444340
Biochem J. 2007 Feb 15;402(1):17-23
17155929
Anal Biochem. 2005 Apr 1;339(1):165-73
15766724
J Gen Virol. 2004 Jun;85(Pt 6):1791-1799
15166465
Science. 1982 Apr 9;216(4542):136-44
6801762
Adv Protein Chem. 2001;57:203-28
11447691
Biomacromolecules. 2007 Nov;8(11):3578-83
17918894
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9741-6
17535913
Lab Invest. 1991 Dec;65(6):622-30
1684401
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14529-34
10588739